Background and Purpose-Limited data are available concerning the outcome of angioplasty/stenting for subacute atherosclerotic intracranial artery occlusion, which is often associated with progressive symptom development in the salvageable brain under ischemic threat due to poor collateral blood supply. Methods-Among 177 patients who underwent angioplasty and/or stenting for severe symptomatic intracranial stenoocclusion, 26 had subacute atherosclerotic intracranial artery occlusion. Outcome after stenting (Nϭ22) was assessed according to procedural success (return of antegrade flow and residual stenosis Ͻ50%), adverse event (any stroke or death) rate, and restenosis (Ͼ50%) using weighted Cox proportional hazards regression in the overall cohort and in separate subgroups. Results-Successful recanalization was achieved in 95%. Three adverse events (13.6%) occurred among patients undergoing stenting for occlusion, including 2 major strokes and 1 nonprocedure-related death. Good outcome (modified Rankin Scale Յ2) was achieved in 73%. In the overall cohort, no significant difference was observed between the occlusion and stenosis groups in terms of the risk of adverse events (hazard ratio for the occlusion group, 1.055; 95% CI, 0.29 -3.90) or the risk of restenosis (hazard ratio for the occlusion group, 1.2; 95% CI, 0.19 -7.72). A trend toward a higher rate of adverse events was observed in older age (Ͼ65 years), progressive worsening, balloon-expandable stent, and no history of a preprocedural P2Y12 assay. Conclusions-In a cohort of patients undergoing angioplasty/stenting for subacute atherosclerotic intracranial artery occlusion, no significant difference in the rates of adverse events was observed. However, several factors, including age, tended to be associated with a higher event rate. (Stroke. 2011;42:3470-3476.)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.